Novo Nordisk partners with OpenAI to upskill its workforce and spearhead artificial intelligence-led healthcare transformation.
Novo Nordisk has announced a strategic partnership with OpenAI, positioning the company at the forefront of artificial intelligence (AI) transformation in healthcare and accelerating the delivery of new treatments to patients.
The collaboration will see advanced AI capabilities applied to analyse complex datasets, identify promising drug candidates, and reduce the time taken to progress from research to patient. The partnership has been established with strict data protection, governance, and human oversight to ensure ethical and compliant use.
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” says Mazier Mike Doustdar, President and CEO of Novo Nordisk.
“Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.”
OpenAI will also support Novo Nordisk in upskilling its global workforce and strengthening AI literacy. In addition, the partnership will apply AI capabilities to enhance efficiency across manufacturing, supply chain and distribution, and corporate operations. Pilot programmes will also be launched across R&D, manufacturing, and commercial operations, with full integration targeted by the end of 2026.
“AI is reshaping industries, and in life sciences, it can help people live better, longer lives,” adds Sam Altman, CEO of OpenAI.
“This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
The agreement builds on Novo Nordisk’s existing AI initiatives, including collaborations with technology partners and research organisations to develop best-in-class capabilities.
Headquartered in Denmark, Novo Nordisk is a leading global healthcare organisation. Since its inception in 1923, the company has delivered on its purpose to drive change, defeat serious chronic illness, and build upon its heritage in diabetes.
Novo Nordisk achieves this by pioneering scientific breakthroughs, expanding access to cutting-edge medicines, and working to prevent and ultimately cure disease across its global footprint of 170+ countries.
